A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
COVID-19 accelerates the progression of atherosclerotic plaques, increasing coronary inflammation and the risk of high-risk ...
To see how the coronavirus that causes COVID-19, SARS-CoV-2, might affect coronary arteries that supply blood to the heart, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback